Table 2.
Distributions of Representative Genomic Alterations and Clinical Characteristics Between the Different Pathological Subtypes with Glioma
| Variable | PA (N=6) | A/AA (N=20) | O/AO (N=17) | GBM (N=32) | DMG (N=8) | P |
|---|---|---|---|---|---|---|
| TP53 | 0 | 13 | 3 | 15 | 3 | 0.0101 |
| TERT | 0 | 1 | 6 | 19 | 2 | 0.0005 |
| IDH1/2 | 0 | 11 | 12 | 4 | 0 | <0.0001 |
| PTEN | 0 | 3 | 0 | 12 | 1 | 0.0123 |
| EGFR | 0 | 0 | 0 | 13 | 0 | <0.0001 |
| ATRX | 0 | 7 | 1 | 6 | 1 | 0.1318 |
| H3F3A | 0 | 0 | 0 | 0 | 8 | <0.0001 |
| NF1 | 0 | 2 | 1 | 4 | 1 | 0.8623 |
| PDGFRA | 0 | 0 | 1 | 5 | 2 | 0.1627 |
| CIC | 0 | 1 | 6 | 0 | 0 | 0.0004 |
| PIK3CA | 0 | 0 | 0 | 4 | 3 | 0.0095 |
| SETD2 | 1 | 0 | 3 | 3 | 0 | 0.2862 |
| MET | 0 | 2 | 0 | 4 | 0 | 0.41 |
| ATM | 0 | 1 | 2 | 1 | 1 | 0.6484 |
| BRAF | 0 | 3 | 1 | 1 | 0 | 0.3771 |
| KIT | 0 | 0 | 0 | 4 | 1 | 0.2211 |
| APC | 0 | 0 | 1 | 3 | 0 | 0.5231 |
| ARID1A | 0 | 3 | 0 | 0 | 1 | 0.0801 |
| CDK4 | 0 | 0 | 1 | 2 | 1 | 0.6393 |
| KDR | 0 | 1 | 0 | 2 | 1 | 0.6739 |
| BRCA1 | 0 | 1 | 0 | 1 | 1 | 0.5905 |
| CDKN2A | 0 | 0 | 0 | 2 | 1 | 0.3975 |
| EPCAM | 0 | 1 | 0 | 1 | 1 | 0.5905 |
| FGFR1 | 0 | 0 | 2 | 0 | 1 | 0.1242 |
| FUBP1 | 0 | 0 | 3 | 0 | 0 | 0.0167 |
| NOTCH1 | 0 | 1 | 1 | 1 | 0 | 0.9234 |
| MGMT | 2 | 13 | 13 | 15 | 0 | 0.0042 |
| 1p19q | 0 | 0 | 10 | 0 | 0 | <0.0001 |
| CNV | 0 | 2 | 2 | 18 | 4 | 0.0004 |
| Age≤40 | 5 | 9 | 7 | 3 | 5 | 0.0007 |
| Age>40 | 1 | 11 | 10 | 29 | 3 | |
| Male | 6 | 14 | 13 | 23 | 4 | 0.344 |
| Female | 0 | 6 | 4 | 9 | 4 |
Note: CNV, the number of glioma patients with CNV events.